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We report 2 cases of Plasmodium falciparum malaria 
in southern France in a French woman and an American 
man of Togolese origin who reported no recent travel to 
malaria-endemic countries. Both infections occurred after a 
stay near Marseille, which raises the possibility of autoch-
thonous transmission. Entomologic and genotypic investi-
gations are described.
E
ndemic malaria was eradicated from France during 
the middle of the past century. However, Plasmodium 
falciparum malaria has recently been reported in several 
Western European countries in persons with no history of 
travel or blood transfusion (1–3). The most recent case of 
an autochthonous case of vivax malaria was reported in 
2006 in Corsica, where susceptible vectors persist (4). In 
southern France, a favorite destination for tourists, the last 
malaria cases in patients without any recent travel in ma-
laria-endemic areas were reported in 1994 and 2000 (5,6). 
We report 2 cases that occurred in southern France during 
early spring and early summer 2006.
The Cases
On June 30, 2006, a 41-year-old woman was admit-
ted to the North University Hospital in Marseille, France, 
with a 12-day history of fever, chills, and diarrhea. She had 
never traveled outside Europe and had no history of blood 
transfusion or injection drug use. She was born in Marseille 
and had lived there her entire life. Her home residence was 
>20 km from the nearest airport and 10 km from the sea-
port. The case-patient did not work outside the home and 
did not report any recreational activities near either loca-
tion. Her neighborhood included families of Comorian de-
scent. Laboratory testing demonstrated low leukocyte and 
erythrocyte counts and thrombocytopenia. Peripheral blood 
smear also demonstrated intra-erythrocytic forms consis-
tent with P. falciparum infection with a parasitemia level of 
0.1%. P. falciparum antigen was detected (Test NowICT; 
Fumouze, Levallois-Perret, France) and subsequently con-
ﬁ  rmed by PCR. Treatment comprised a 3-day regimen of 
quinine-clindamycin (7) and the case-patient recovered.
A 34-year-old man with tactile fever, bilateral frontal 
headache, and diarrhea was examined at a clinic in Min-
neapolis, Minnesota, on May 1, 2006. This man had lived 
in Togo, his birth country, all of his life until he emigrated 
to Minnesota in April 2000. Before becoming ill, he had 
traveled to Paris and from Paris by train to Marseille on 
April 7, 2006. Also during this timeframe, he reported a 
day trip to Camargue (Sorgues, France) where he sustained 
multiple mosquito bites. On April 24, 2006, he returned to 
Paris by train and then traveled by air a few hours later to 
Minneapolis. The ﬁ  rst symptoms of malaria developed on 
April 27. His medical history included 4 episodes of ma-
laria in childhood (none in the past decade) and no blood 
transfusions. On his last visit to Togo in December 2004, 
the case-patient had reported no chemoprophylaxis for ma-
laria and had experienced no illness or intervening fevers 
since that time. Physical examination showed a moderately 
ill person with hematologic test results indicating thrombo-
cytopenia and intra-erythrocytic ring forms consistent with 
P. falciparum malaria with a 3% parasitemia level. PCR 
testing conﬁ  rmed P. falciparum. He was given 4 tablets of 
atovoquone-proguanil once a day for 3 days and recovered 
completely.
We conducted entomologic surveillance on July 26, 
2006, in and around the ﬁ  rst case-patient’s residence in 
Marseille, 26 days after she became ill. No adult mosqui-
toes were found in the patient’s home, on external stair-
cases, in cellars located around the patient’s home, or in 
surrounding buildings. Two pools of standing water were 
identiﬁ  ed: a single pool (1 m2, 2 cm deep) within a cellar in 
her building and another pool (10 m2, 5 cm deep) located 20 
m outside the building. No other containers or places that 
could collect water were identiﬁ  ed. Several Culex theileri 
larvae were identiﬁ  ed in the outdoor pool, but there was no 
evidence of Anopheles larvae.
DNA was extracted from blood samples by using the 
ENZA blood DNA kit according to the manufacturer’s 
recommendations (Bioﬁ  dal, Vaulx en Velin, France) and 
eluted in 100 μL of elution buffer per 250 μL of whole 
blood. Microsatellites loci (C4M79, Pf2689, TRAP, 
Pf2802, 7A11, and C4M69) were genotyped by ﬂ  uorescent 
end-labeled PCR. Primers sequence, PCR conditions, and 
methods for genotyping have been described elsewhere 
(8,9). Drug-resistant mutations were genotyped. Genotyp-
ing of the 2 isolates demonstrated different alleles for the 6 
microsatellite loci. We also observed different alleles from 
codon 59 (dihydrofolate reductase), 437 (dihydropteroate 
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synthase), and 76 (P. falciparum chloroquine-resistance 
transporter) (Tables 1, 2).
Conclusions
The World Health Organization deﬁ  nes introduced au-
tochthonous malaria as that acquired by mosquito transmis-
sion from an imported case in an area where malaria is not 
a regular occurrence (10) In France, it is rare to ﬁ  nd P. fal-
ciparum in a blood smear from patients who have not trav-
eled to a malaria-endemic area in the previous 12 months. 
History of transfusion, organ transplantation, intravenous 
drug use, or mother-to-fetus transmission must also be ex-
cluded (10).
In Europe, some recent autochthonous malaria cases 
have been related to close proximity to airports and ship-
ping ports receiving ﬂ  ights and water craft from malaria-
endemic areas (5,6,11). Inadvertent carriage of infective 
Anopheles mosquitoes by airplane, ship, baggage, or bilge 
water may be responsible for these occurrences. Also, large 
populations of migrants from areas highly endemic for ma-
laria (12) may act as human reservoirs for potential game-
tocyte carriers. Marseille has a large population of persons 
of Comorian origin, and most of the patients with imported 
malaria cases diagnosed in Marseille contracted the disease 
during a trip to the Comoros Islands (13,14). Our ﬁ  rst case-
patient’s malaria may have been linked to her neighbor-
hood, which included Comorian families who had recently 
traveled to Comoros. Despite the absence of Anopheles 
larvae near the ﬁ  rst patient’s neighborhood, local transmis-
sion cannot be excluded during the late spring and sum-
mer. Summer temperatures in Marseille induce a short 
P. falciparum sporogonic cycle (≈11 days at 28°C), which 
is compatible with mosquitoes’ longevity at that time.
The Minnesota case-patient likely represents a second 
case of autochthonous malaria. First, this patient had no ill-
ness to suggest an untreated, active infection since his last 
trip to Togo. Second, even if he had been persistently in-
fected with P. falciparum and was semi-immune, this case 
would still represent an extremely long incubation period 
(16 months). Third, onset of symptoms was acute, hemato-
logic testing showed infection with a 3% parasitemia level, 
and the case-patient was moderately ill, which suggests a 
more recent exposure. Moreover, the genotype was mono-
allelic for each locus, indicating a clonal infection, which 
would be expected in areas of relatively low transmission 
frequency. In contrast, in areas of frequent endemic trans-
mission, such as Togo, multiple allelic polymorphisms 
would be expected (9). Finally, genotyping demonstrated 
different clones of P. falciparum; this ﬁ  nding suggests po-
tential multiple introductions, temporally related, of the 
parasite into the environment
The last malaria focus in continental France occurred 
near the end of World War II in the Camargue region, 
which was visited by our second case-patient in April 
2006. However, large Anopheles populations, including 
potential vectors such as An. hyrcanus, An. melanoon, and 
An. atroparus, are still present from March to November 
(N. Ponçon and D. Fontenille, unpub.data) in southeastern 
France, generating an “anophelism without malaria” situa-
tion (15).
Migrants from malaria-endemic countries, climate, 
and Anopheles populations make southern France a favor-
able area for sporadic cases of autochthonous malaria in 
Europe. Given these 2 temporally related cases, clinicians 
should suspect malaria in patients with unexplained fevers 
who have recently traveled to areas of southern France.
Table 1. Microsatellite loci genotyping and single nucleotide polymorphism in drug-resistant genes  
C4M79 Pf2689 Pf2802 7A11 C4M69 TRAP
Autochthonous 1* 190 87 141 88 378 132
Autochthonous 2† 221 95 138 99 364 149
3D7‡ 221 87 138 94 364 137
W2‡ 188 87 146 109 319 140
*Patient 1, Plasmodium falciparum diagnosed in France. 
†Patient 2, P. falciparum diagnosed in the United States. 
‡Two parasite strains (3D7 and W2) were genotyped as a positive control; water was used as a negative control. 
Table 2. Two strains of Plasmodium falciparum obtained from 2 patients with no recent travel history in malaria-endemic areas* 
Dhfr Dhps Pfcrt
51 16 108 164 59 613 540 581 436 437 76
Autochthonous 1†  – GCA AAC ATA TGT GCC AAA GCG TCT GCT ACA
Autochthonous 2‡ ATT GCA AAC ATA CGT GCC AAA GCG TCT GGT AAA
3D7§ AAT GCA AGC ATA TGT GCC AAA GCG TCT GGT AAA
W2§ ATT GCA AAC ATA CGT TCC AAA GCG TTT GGT ACA
*Dhfr, dihydrofolate reductase gene; Dhps, dihydropteroate synthase; Pfcrt, P. falciparum chloroquine-resistance transporter. Underlines indicate 
positions that can be mutated. 
†Patient 1, P. falciparum diagnosed in France. 
‡Patient 2, P. falciparum diagnosed in the United States. 
§Two parasite strains (3D7 and W2) were genotyped as a positive control; water was used as a negative control.  DISPATCHES
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